Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage
Trial Parameters
Brief Summary
Postpartum hemorrhage (PPH) is the global leading cause of maternal death, with 20-30% of maternal deaths in Thailand linked to hemorrhage. The WOMAN Trial (2017) provided strong evidence that administering tranexamic acid (TXA)within three hours of bleeding onset lowered PPH-related mortality by 31%. Consequently, the World Health Organization (WHO) updated its guidelines, recommending TXA as part of the standard treatment package for all PPH cases. Following this, the use of TXA has been widely adopted globally and increased in Thailand. A recent study at a major Thai university hospital observed a significant increase in TXA administration after 2017. The current study aims to further analyze the recent growth rate of TXA use and its impact on obstetric and perinatal outcomes during cesarean deliveries with PPH.
Eligibility Criteria
Inclusion Criteria: * 1\. Patients underwent cesarean delivery with primary postpartum hemorrhage Exclusion Criteria: 1. Gestational age at less than 24 weeks 2. Absence of the anesthetic record 3. Received tranexamic acid in the antepartum period 4. Blood loss less than 1,000 ml